Highlights of This Issue 4497

SPECIAL FEATURES

CCR 20th Anniversary Commentary

4499 CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer
Mohammad Aminur Rahman and Dong M. Shin

CCR Translations

4502 Imaging Tumor Acidity: pH-Low Insertion Peptide Probe for Optoacoustic Tomography
Yana K. Reshetnyak
See related article, p. 4576

4505 Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch
Tian Zhang and Andrew J. Armstrong
See related article, p. 4619

Molecular Pathways

4508 Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
Fabio Conforti, Yisong Wang, Jose A. Rodriguez, Anna Teresa Alberobello, Yu-Wen Zhang, and Giuseppe Giaccone

Review

4514 Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
Jaegil Kim, Rehan Akbani, Chad J. Creighton, Seth P. Lerner, John N. Weinstein, Gad Getz, and David J. Kwiatkowski

CCR Focus

4526 On Innovating and Inspiring the Clinical Trial Enterprise
Susan E. Bates

4527 Advancing Clinical Trials to Streamline Drug Development
Susan E. Bates, Donald A. Berry, Sanjeeve Balasubramaniam, Stuart Bailey, Patricia M. LoRusso, and Eric H. Rubin

4536 Next-Generation Sequencing to Guide Clinical Trials
Lillian L. Siu, Barbara A. Conley, Scott Boerner, and Patricia M. LoRusso

4545 Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
Marc R. Theorene, Lee H. Pui-Scherf, Meredith K. Chuk, Tatiana M. Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G. Kluetz, Patricia Keegan, and Richard Pazdur

4552 Failures in Phase III: Causes and Consequences
Bostjan Seruga, Alberto Ocana, Eitan Amir, and Ian F. Tannock

4561 The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases
David J. Stewart, Gerald Batist, Hagop M. Kantarjian, John-Peter Bradford, Joan H. Schiller, and Razelle Kurzrock

CANCER THERAPY: CLINICAL

4569 Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer

PERSONALIZED MEDICINE AND IMAGING

4576 Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo
Charles W. Kimbrough, Anil Khanal, Matthew Zeiderman, Bigya R. Khanal, Neal C. Burton, Kelly M. McMasters, Selwyn M. Vickers, William E. Grizzle, and Lacey R. McNally
See related commentary, p. 4502
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies
Netanya I. Pollock, Lin Wang, Gerald Wallweber, William E. Gooding, Weidong Huang, Ahmed Chenna, John Winslow, Malabika Sen, Kara A. DeGrave, Hua Li, Yan Zeng, and Jennifer R. Grandis

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Di Cui, Jinli Dai, Jill M. Keller, Atsushi Mizokami, Shujie Xia, and Evan T. Keller
See related commentary. p. 4505

Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice
Sun-Jin Kim, Ho Jeong Lee, Mark Seungwook Kim, Hyun Jin Choi, Junquin He, Qiyu Wu, Kenneth Aldape, Jeffrey S. Weinberg, W.K. Alfred Yung, Charles A. Conrad, Robert R. Langley, and Owen A. O’Connor

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Carminia Maria Della Corte, Claudio Belleviscne, Giovanni Vicidomini, Donata Vitaglione, Umberto Malapelle, Marina Accardo, Alessio Fabozzi, Alfonso Fiorelli, Morena Fasano, Federica Papaccio, Erika Martinelli, Teresa Troiani, Giancarlo Tromcone, Mario Santini, Roberto Bianco, Fortunato Ciardiello, and Floriana Morgillo

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4719</td>
<td>Keap1–Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein</td>
<td>Ming-Hsien Chien, Wei-Jiunn Lee, Feng-Koo Hsieh, Chia-Feng Li, Tsu-Yao Cheng, Ming-Yang Wang, Jin-Shing Chen, Jyh-Ming Chow, Yi-Hua Jan, Michael Hsiao, Kuo-Tai Hua, and Min-Liang Kuo</td>
</tr>
<tr>
<td>4740</td>
<td>Siltuximab for Multicentric Castleman Disease—Letter</td>
<td>Raphael Teipel, Rainer Odermann, Ulrike Proske, Frank Dietrich, Marika Mende, Gerhard Ehninger, Frank Kroschinsky, and Uwe Platzbecker</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

This is a section of human LN-229 glioblastoma growing in the brain of nude mice. Immunohistochemical staining shows heterogeneous expression of endothelin receptors ET₆R depicted in green and ET₃R depicted in red. For details see the article by Kim and colleagues on page 4630 of this issue.